Search Results

December 2021 "30/11/2021 Confo will work together with Regeneron to apply its GPCR drug discovery platform VIB spin-off Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022 Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain "— Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled

I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical medicinal chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics . Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.

In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Pharmacology - Australia GPCR Jobs NEW Open Postdoctoral position - Stanford University Structural Biologist - Confo Therapeutics Associate Director/Director, Platform & Hit-ID Chemistry Lead - Septerna Junior associate